New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of virtual cardiologists and care

Cleerly, the company creating a new standard of care for heart disease, and Heartbeat Health, the nation's largest virtual-first cardiovascular company, today announced a partnership to use precision heart health to more accurately determine cardiovascular risk and deliver better heart care.

Cleerly’s AI-enabled approach for evaluating coronary computed tomography angiography (CCTA) allows physicians to more easily identify, characterize and quantify atherosclerosis (plaque) buildup in the walls of heart arteries. This AI-powered scan provides a more accurate understanding of a patient’s risk of heart attack and improves on historical assessments of heart disease that use indirect surrogate markers of disease. Heartbeat Health offers real-time clinical data and device connectivity to deliver a range of clinical offerings, including same-day diagnostic reads, televisits and care programs. Heartbeat Health's nationwide team of virtual cardiologists provide better care wherever patients might be.

The companies’ joint offering expands on the recent American College of Cardiology guidelines regarding the use of CCTA for non-invasive heart disease evaluation. The ability for any individual to proactively obtain a CCTA test in their area with Cleerly’s AI-enabled analysis — and then connect live with a Heartbeat Health virtual cardiologist to discuss a treatment plan — is a game-changing development for the estimated 8 million people¹ who should be getting a CCTA annually.

“Surrogate markers too often fail patients as predictors and miss the majority of patients who will suffer a heart attack. In fact, more than half of all patients who experience a heart attack show no symptoms before they have one. We can do better,” said Dr. Jeff Wessler, a virtual cardiologist and Heartbeat Health's co-founder and CEO. "Working with Cleerly, we can improve diagnostic clarity to personalize therapeutic choices that offer both clinical benefit and reduce the risk of a catastrophic cardiac event.”

Together, Heartbeat Health and Cleerly are increasing access to early cardiac evaluations and will offer value-based offerings for health providers, payers, payviders and at-risk primary care practices.

“At Cleerly, we’re working to make CCTA-based evaluation the new standard of cardiovascular care to proactively identify the early stages of heart disease, when we can prevent its progression more easily,” said James Min, MD, FACC, FESC, MSCCT, CEO and founder of Cleerly. “With Heartbeat’s staff of cardiologists licensed in every state in the U.S., we’ll be able to help flagged patients move swiftly into an efficacious and cost-effective care plan, with convenient same-day video visits.”

This joint offering is now available directly to patients across the United States. Individuals who are interested in getting a CCTA exam with a Cleerly analysis can visit Cleerly’s website for more information.

About Heartbeat Health

Heartbeat Health is a Virtual-First Cardiology solution revolutionizing the delivery of cardiovascular care. Cardiology, like many specialties, is reactive with a focus on the already sick; Our Virtual-first model delivers preventive measures before heart health conditions develop and progress. Heartbeat leverages real-time clinical data and device connectivity to diagnose and deliver proactive heart care - helping provider groups and healthcare organizations identify, monitor, and manage cardiovascular care for their at-risk member populations. Powered by a connected ecosystem of heart health providers, Heartbeat delivers a range of clinical services, including same-day diagnostic reads, televisits, and virtual care programs for patients with atrial fibrillation, vascular disease, and heart failure. Virtual-First Cardiology has arrived. Learn more at www.heartbeathealth.com.

About Cleerly

Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.

^{1Oliver Wyman: 8 Million Nuclear Stress Tests are Performed in the US. Is this Necessary?}

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005159/en/